LOUISVILLE, Colo., Dec. 15 /PRNewswire/ -- GlobeImmune, Inc. today announced the relocation of its corporate headquarters to Louisville, Colorado.
The new GlobeImmune address is: 1450 Infinite Drive Louisville, Colorado 80027 The telephone number is: 303-625-2700 The main fax number is: 303-625-2710 The website address remains unchanged: www.globeimmune.com About GlobeImmune, Inc.
GlobeImmune, Inc. is an emerging biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapy products called Tarmogens for the treatment of cancer and infectious diseases. The Company's lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, is currently in Phase 1 clinical trials. The Company initiated a Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005.
Tarmogens are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein antigens that stimulate the immune system against diseased cells. Tarmogens are avidly taken up by the cells that activate the immune system called antigen presenting cells, to stimulate a so-called "killer T cell" response against the desired target(s). GlobeImmune's patented Tarmogen platform has a number of advantages over current approaches including that Tarmogens generate potent T cell immune responses, are not neutralized by the immune system, can be rapidly engineered and are simple to manufacture.
For additional information, please visit the company's website at www.globeimmune.com.
GlobeImmune, Inc.CONTACT: Timothy C. Rodell, M.D., Chief Executive Officer of GlobeImmune,Inc., +1-303-625-2700, or fax, +1-303-625-2710, information@globeimmune.com
Web site: http://www.globeimmune.com/
